DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand [Yahoo! Finance]
DaVita Inc. (DVA)
Last davita inc. earnings: 2/10 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.davita.com/investor-relations
Company Research
Source: Yahoo! Finance
The figure surpassed the Zacks Consensus Estimate by 5.1%. GAAP EPS from continuing operations for the quarter was $2.94, reflecting a decline of 4.9% year over year. Full-year adjusted EPS was $10.78, reflecting a 11.4% increase from the year-ago period. The figure beat the Zacks Consensus Estimate by 0.7%. Revenues of $3.62 billion in the fourth quarter increased 9.9% year over year. The figure topped the Zacks Consensus Estimate by 2.7%. Revenue per treatment (RPT) in the fourth quarter of 2025 was $422.6 million, up 6.8% year over year and 2.9% sequentially. Per management, this was primarily driven by the resolution of aged receivables, normal rate increases and improved yield, a slight improvement in private pay mix after a dip in the third quarter and the typical seasonal impact of flu vaccines. Full-year revenues were $13.64 billion, reflecting a 6.5% improvement from the year-ago period. The metric topped the Zacks Consensus Estimate by 0.7%. Shares of this compan
Show less
Read more
Impact Snapshot
Event Time:
DVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVA alerts
High impacting DaVita Inc. news events
Weekly update
A roundup of the hottest topics
DVA
News
- DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year ImprovementPR Newswire
- Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306PR Newswire
- Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306PR Newswire
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney diseaseGlobeNewswire
DVA
Earnings
- 2/2/26 - Beat
DVA
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- DVA's page on the SEC website